Balance Sheet
Cash Flow Statement
Change in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in TaxesChange in TaxesGains from Equity InvestmentsGains from Equity InvestmentsGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zepp Health (ZEPP) Gains from Sales and Divestitures (2016 - 2025)

Zepp Health has reported Gains from Sales and Divestitures over the past 9 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, changed N/A, while the annual FY2025 figure was $1.5 million, 396.81% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $1.5 million at Zepp Health, up from $224537.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $1.5 million in Q4 2025 and troughed at $80968.1 in Q4 2021.
  • A 4-year average of $489006.1 and a median of $201440.2 in 2022 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: tumbled 45.63% in 2021 and later surged 120.26% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $80968.1 in 2021, then surged by 120.26% to $178343.3 in 2022, then rose by 25.9% to $224537.0 in 2023, then surged by 555.65% to $1.5 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for ZEPP at $1.5 million in Q4 2025, $224537.0 in Q4 2023, and $178343.3 in Q4 2022.